The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
XL JAK2 BA
Break Apart Probe
- Order Number
- Package Size
- 100 µl
Patients with clinical characteristics of CML lacking a BCR/ABL fusion gene are usually
referred to as having atypical CML. Most commonly diverse tyrosine kinase genes as the
receptors FGFR1, PDGFRA, or PDGFRB are involved. In addition the Janus (tyrosine)
kinases (JAK) can be deregulated in leukemia/lymphoma by copy number alterations, mutations and chromosomal translocations.
Chromosomal translocations targeting JAK2 are rare but recurrent abnormalities in myeloproliferative neoplasms, acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma. In cell line models and primary patient material it could be shown that treatment with ruxolitinib has significant activity against JAK2 activated by gene rearrangement and presents evidence for potential activity against cells with JAK2 amplification.
- Chronic Myelogenous Leukemia and Myeloproliferative Neoplasms (CML/MPN)
- Acute Myelogenous Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
Two green-orange fusion signals (2GO).
Aberrant Cell (typical results):
One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the JAK2 locus.
- Bousquet et al (2005) Oncogene 24: 7248- 7252
- Chase et al (2012) Haematologica 93: 404- 408
- Ehrentraut et al (2013) PLOSone 8: e53767